|
In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL. |
|
|
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda |
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda |
|
|
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichi Sankyo (Inst); ImmunoGen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical |
Consulting or Advisory Role - Abbvie |
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst) |
|
|
Honoraria - Amgen; Jazz Pharmaceuticals; Pfizer; Sobi; Takeda |
Consulting or Advisory Role - (Takeda; Amgen; Jazz Pharmaceuticals; Pfizer; Sobi |
Speakers' Bureau - Pfizer |
Research Funding - AbbVie; MacroGenics |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Takeda |
Speakers' Bureau - Servier |
Research Funding - Abbvie; Daiichi Sankyo; Novartis; Servier; Takeda |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Kite/Gilead; Pfizer; Takeda |
Travel, Accommodations, Expenses - Adaptive Biotechnologies |
|
|
Consulting or Advisory Role - BMS; Janssen; Takeda; Teva |
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb (Mexico); Janssen; Novartis; Takeda |
|
|
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); FORMA Therapeutics (Inst); Kite, a Gilead company (Inst); Kura Oncology (Inst); Takeda (Inst) |
|
Carlo Gambacorti-Passerini |
No Relationships to Disclose |
|
|
Honoraria - BluPrint Oncology; Bristol-Myers Squibb/Pfizer |
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb/Pfizer; Novartis |
Speakers' Bureau - Amgen; BluePrint Health; Bristol-Myers Squibb/Pfizer; Incyte; Jazz Pharmaceuticals; Stemline Therapeutics; Takeda |
|
|
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Novartis; Pfizer; Takeda |
Speakers' Bureau - Astellas Pharma; Daiichi Sankyo; Novartis; Pfizer |
Research Funding - Novartis; Ono CMIC |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; Cogent Biosciences; CTI BioPharma Corp; Genentech/Roche; GlaxoSmithKline; Incyte; Karyopharm Therapeutics; Merck; MorphoSys; Novartis; Pfizer; Stemline Therapeutics |
Speakers' Bureau - Blueprint Medicines; Incyte |
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Immunogen; Janssen; Kite/Gilead; Kura Oncology; Novartis; Nuprobe; Qiagen; Rigel; Schrodinger; Sellas Life Sciences; Sumitomo Pharma Oncology; Syndax |
Speakers' Bureau - Astellas Pharma; DAVA Pharmaceuticals; Pfizer |
Other Relationship - Abbvie/Genentech; Gilead Sciences; Gilead Sciences |
|
|
|
|
|
|
|
|
|
|
|
|
|
Jose-Maria Ribera-Santasusana |
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Novartis; Pfizer; Takeda |
Research Funding - AMGEN; Incyte; Pfizer |